https://www.targetedonc.com/view/tmb-tumor-burden-and-tailoring-immunotherapy-in-lung-cancer2026-06-03T21:00:00Z2026-06-03T21:00:00Z https://www.targetedonc.com/view/long-term-outcomes-offer-reassurance-on-quadruplet-use-in-transplant-ineligible-ndmm2026-06-03T21:00:00Z2026-06-03T21:00:00Z https://www.targetedonc.com/view/allostatic-load-emerges-as-a-risk-marker-for-early-onset-cancer2026-06-03T20:00:00Z2026-06-03T20:00:00Z https://www.targetedonc.com/view/fda-approves-expanded-automated-pd-l1-diagnostic-testing-across-four-solid-tumor-types2026-06-03T19:00:00Z2026-06-03T19:00:00Z https://www.targetedonc.com/view/dr-tolaney-on-sg-pembrolizumab-biomarker-data-in-first-line-mtnbc2026-06-03T18:00:00Z2026-06-03T18:00:00Z https://www.targetedonc.com/view/velzatinib-aims-for-future-direct-comparison-with-imatinib-in-gist2026-06-03T17:00:00Z2026-06-03T17:00:00Z https://www.targetedonc.com/view/asco-2026-gu-cancer-highlights-beyond-the-lbas2026-06-03T15:30:00Z2026-06-03T15:30:00Z https://www.targetedonc.com/view/fda-approves-generic-eribulin-mesylate-for-metastatic-breast-cancer2026-06-03T14:00:00Z2026-06-03T14:00:00Z https://www.targetedonc.com/view/dr-mardones-on-giredestrant-s-numerical-pfs-edge-in-advanced-breast-cancer2026-06-03T10:00:00Z2026-06-03T10:00:00Z https://www.targetedonc.com/view/dr-saad-on-long-term-safety-of-177lu-psma-617-in-mhspc2026-06-02T20:00:00Z2026-06-02T20:00:00Z https://www.targetedonc.com/view/leveraging-ctdna-subgroups-and-clearance-metrics-for-velzatinib-in-gist2026-06-02T19:30:00Z2026-06-02T19:30:00Z https://www.targetedonc.com/view/fda-oks-oral-nilotinib-tablets-for-ph-cml-with-acid-reducer-flexibility2026-06-02T19:15:00Z2026-06-02T19:15:00Z https://www.targetedonc.com/view/revumenib-maintenance-after-allogeneic-sct-shows-feasibility-in-aml2026-06-02T18:30:00Z2026-06-02T18:30:00Z https://www.targetedonc.com/view/tucatinib-maintenance-improves-pfs-across-key-subgroups-in-her2-mbc2026-06-02T18:11:56.267Z2026-06-02T18:11:56.267Z https://www.targetedonc.com/view/gedatolisib-combinations-double-pfs-in-pik3ca-mutant-breast-cancer2026-06-02T17:38:00Z2026-06-02T17:38:00Z https://www.targetedonc.com/view/bispecific-adc-iza-bren-extends-survival-in-advanced-tnbc2026-06-02T16:41:00Z2026-06-02T16:41:00Z https://www.targetedonc.com/view/disc-0974-produces-meaningful-hematologic-responses-in-myelofibrosis-associated-anemia2026-06-02T16:03:55.529Z2026-06-02T16:03:55.529Z https://www.targetedonc.com/view/fda-grants-priority-review-to-giredestrant-for-er-her2--breast-cancer2026-06-02T15:00:00Z2026-06-02T15:00:00Z https://www.targetedonc.com/view/targeting-il-2-pathway-overcome-immunotherapy-resistance-melanoma2026-06-02T15:00:00Z2026-06-02T15:00:00Z https://www.targetedonc.com/view/timothy-cloughesy-asco-2026-extended-follow-up-indigo-trial2026-06-02T14:00:00Z2026-06-02T14:00:00Z https://www.targetedonc.com/view/sacituzumab-govitecan-plus-pembro-sustains-benefit-beyond-first-progression-in-pd-l1-positive-mtnbc2026-06-02T12:00:00Z2026-06-02T12:00:00Z https://www.targetedonc.com/view/2026-asco-plenary-delivers-practice-changing-progress2026-06-02T10:00:00Z2026-06-02T10:00:00Z https://www.targetedonc.com/view/psmaddition-177lu-psma-617-benefits-mhspc-across-disease-burdens2026-06-01T20:00:00Z2026-06-01T20:00:00Z https://www.targetedonc.com/view/keynote-942-asco-5-years-personalized-mrna-vaccine-melanoma2026-06-01T19:30:46.381Z2026-06-01T19:30:46.381Z https://www.targetedonc.com/view/ivonescimab-combo-shows-superior-overall-survival-in-advanced-squamous-nsclc2026-06-01T18:30:00Z2026-06-01T18:30:00Z https://www.targetedonc.com/view/rilvegostomig-t-dxd-shows-promise-immune-positive-her2-early-breast-cancer2026-06-01T18:01:52.621Z2026-06-01T18:01:52.621Z https://www.targetedonc.com/view/shubham-pant-asco-2026-daraxonrasib-pancreatic-cancer2026-06-01T18:00:00Z2026-06-01T18:00:00Z https://www.targetedonc.com/view/adjuvant-intismeran-pembro-shows-durable-benefit-at-5-years-in-melanoma2026-06-01T15:30:00Z2026-06-01T15:30:00Z https://www.targetedonc.com/view/zelenectide-pevedotin-plus-pembrolizumab-shows-promise-in-first-line-urothelial-carcinoma2026-06-01T14:05:00Z2026-06-01T14:05:00Z https://www.targetedonc.com/view/elizabeth-mcdonald-asco-2026-glp1-breast-cancer2026-06-01T14:00:00Z2026-06-01T14:00:00Z https://www.targetedonc.com/view/velzatinib-shows-activity-across-kit-mutation-spectrum-advanced-gist2026-06-01T13:49:06.619Z2026-06-01T13:49:06.619Z https://www.targetedonc.com/view/abemaciclib-cuts-progression-risk-by-62-in-dedifferentiated-liposarcoma2026-06-01T13:44:59.827Z2026-06-01T13:44:59.827Z https://www.targetedonc.com/view/durvalumab-tremelimumab-stride-based-regimens-boost-pfs-in-hcc2026-06-01T12:13:55.918Z2026-06-01T12:13:55.918Z https://www.targetedonc.com/view/favorable-3-year-os-observed-with-rp1-nivo-in-advanced-melanoma2026-05-31T22:45:00Z2026-05-31T22:45:00Z https://www.targetedonc.com/view/third-line-treatment-considerations-for-kras-wild-type-mcrc2026-05-31T22:10:05.888Z2026-05-31T22:10:05.888Z https://www.targetedonc.com/view/new-hope-in-gist-peak-trial-advances-second-line-treatment2026-05-31T20:00:00Z2026-05-31T20:00:00Z https://www.targetedonc.com/view/establishing-bcma-targeted-therapy-as-the-second-line-myeloma-standard-of-care2026-05-31T20:00:00Z2026-05-31T20:00:00Z https://www.targetedonc.com/view/disease-stabilization-reflects-clinical-value-of-brenetasfusp-in-melanoma2026-05-31T19:00:00Z2026-05-31T19:00:00Z https://www.targetedonc.com/view/ipatasertib-plus-pembrolizumab-improves-orr-in-recurrent-metastatic-hnscc2026-05-31T17:31:18.118Z2026-05-31T17:31:18.118Z https://www.targetedonc.com/view/talazoparib-plus-enzalutamide-cuts-progression-risk-by-52-in-hrr-altered-mcspc2026-05-31T15:08:13.595Z2026-05-31T15:08:13.595Z https://www.targetedonc.com/view/perioperative-apalutamide-plus-adt-reduces-risk-of-metastasis-or-death-in-high-risk-localized-prostate-cancer2026-05-31T13:54:00Z2026-05-31T13:54:00Z https://www.targetedonc.com/view/daraxonrasib-nearly-doubles-os-versus-chemotherapy-in-metastatic-pdac2026-05-31T12:02:00Z2026-05-31T12:02:00Z https://www.targetedonc.com/view/adjuvant-selpercatinib-significantly-extends-efs-in-ret-fusion-positive-nsclc2026-05-31T12:01:00Z2026-05-31T12:01:00Z https://www.targetedonc.com/view/ultra-low-dose-immunotherapy-plus-oral-metronomic-chemotherapy-effective-in-hnscc2026-05-31T12:00:00Z2026-05-31T12:00:00Z https://www.targetedonc.com/view/bezuclastinib-plus-sunitinib-halves-risk-of-progression-in-second-line-gist2026-05-30T23:04:34.927Z2026-05-30T23:04:34.927Z https://www.targetedonc.com/view/dr-de-boniface-on-encouraging-senomac-trial-data2026-05-30T21:00:00Z2026-05-30T21:00:00Z https://www.targetedonc.com/view/scaling-app-led-consults-in-community-practices2026-05-30T20:00:00Z2026-05-30T20:00:00Z https://www.targetedonc.com/view/durvalumab-monotherapy-misses-dfs-end-point-in-adjuvant-rcc2026-05-30T17:15:37.067Z2026-05-30T17:15:37.067Z https://www.targetedonc.com/view/teclistamab-significantly-improves-os-pfs-versus-standard-regimens-in-rrmm2026-05-30T16:33:58.834Z2026-05-30T16:33:58.834Z https://www.targetedonc.com/view/keynote-522-asco-2026-update2026-05-30T16:00:00Z2026-05-30T16:00:00Z https://www.targetedonc.com/view/tafasitamab-plus-lenalidomide-and-r-chop-cuts-progression-risk-in-high-risk-dlbcl2026-05-30T14:27:39.667Z2026-05-30T14:27:39.667Z https://www.targetedonc.com/view/mezigdomide-triplet-cuts-progression-risk-by-52-in-r-r-myeloma2026-05-30T12:15:00Z2026-05-30T12:15:00Z https://www.targetedonc.com/view/omitting-alnd-is-safe-and-reduces-arm-complications-in-certain-breast-cancer-patients2026-05-30T12:01:00Z2026-05-30T12:01:00Z https://www.targetedonc.com/view/intravesical-recombinant-bcg-plus-chemoimmunotherapy-yields-high-pcr-in-mibc2026-05-30T01:26:47.020Z2026-05-30T01:26:47.020Z https://www.targetedonc.com/view/enfortumab-vedotin-plus-pembro-sustains-long-term-efficacy-in-advanced-urothelial-carcinoma2026-05-30T00:37:38.420Z2026-05-30T00:37:38.420Z https://www.targetedonc.com/view/dreamm-9-identifies-preferred-dosing-strategy-for-belantamab-in-ndmm2026-05-29T23:10:13.640Z2026-05-29T23:10:13.640Z https://www.targetedonc.com/view/relacorilant-os-benefit-sustained-in-ovarian-cancer-regardless-of-prior-taxane-exposure2026-05-29T22:30:00Z2026-05-29T22:30:00Z https://www.targetedonc.com/view/dostarlimab-chemo-shows-curative-potential-in-dmmr-msi-h-advanced-endometrial-cancer2026-05-29T22:00:00Z2026-05-29T22:00:00Z https://www.targetedonc.com/view/the-therapeutic-power-of-early-car-t-intervention-in-the-car-prism-trial2026-05-29T17:30:00Z2026-05-29T17:30:00Z https://www.targetedonc.com/view/fda-orphan-drug-status-awarded-to-eo2463-in-indolent-non-hodgkin-lymphoma2026-05-29T16:00:00Z2026-05-29T16:00:00Z https://www.targetedonc.com/view/fda-grants-priority-review-for-bezuclastinib-plus-sunitinib-in-gist2026-05-28T20:00:00Z2026-05-28T20:00:00Z https://www.targetedonc.com/view/ibrutinib-rituximab-and-fcr-show-comparable-hrqol-in-frontline-cll2026-05-28T19:00:00Z2026-05-28T19:00:00Z https://www.targetedonc.com/view/fda-approves-durvalumab-plus-bcg-for-high-risk-nmibc2026-05-28T18:32:45.124Z2026-05-28T18:32:45.124Z https://www.targetedonc.com/view/fda-grants-fast-track-designation-to-stx-0712-for-r-r-cmml2026-05-28T18:00:00Z2026-05-28T18:00:00Z https://www.targetedonc.com/view/summary-and-key-takeaways-for-first-line-egfr-mutant-nsclc-with-brain-metastases2026-05-28T15:25:00Z2026-05-28T15:25:00Z https://www.targetedonc.com/view/evolving-treatment-landscape-and-future-directions-n-first-line-egfr-mutant-nsclc2026-05-28T15:20:00Z2026-05-28T15:20:00Z https://www.targetedonc.com/view/subcutaneous-amivantamab-and-q4w-dosing-for-first-line-egfr-mutant-nsclc2026-05-28T15:15:00Z2026-05-28T15:15:00Z https://www.targetedonc.com/view/safety-profiles-and-proactive-therapy-management-of-first-line-regimens-in-egfr-mutant-nsclc2026-05-28T15:10:00Z2026-05-28T15:10:00Z https://www.targetedonc.com/view/cns-surveillance-and-long-term-management-in-egfr-mutant-nsclc-with-brain-metastases2026-05-28T15:05:00Z2026-05-28T15:05:00Z https://www.targetedonc.com/view/overall-survival-and-systemic-efficacy-of-first-line-regimens-in-egfr-mutant-nsclc2026-05-28T15:00:00Z2026-05-28T15:00:00Z https://www.targetedonc.com/view/comparing-cns-efficacy-of-first-line-regimens-in-egfr-mutant-nsclc-with-brain-metastases2026-05-28T14:55:00Z2026-05-28T14:55:00Z https://www.targetedonc.com/view/case-presentation-mr-smith-a-53-year-old-man-with-egfr-mutant-nsclc-and-brain-metastases2026-05-28T14:50:00Z2026-05-28T14:50:00Z https://www.targetedonc.com/view/fda-approves-pivekimab-sunirine-for-bpdcn2026-05-28T13:12:00Z2026-05-28T13:12:00Z https://www.targetedonc.com/view/streamlining-the-til-therapy-pipeline-for-melanoma2026-05-28T13:00:00Z2026-05-28T13:00:00Z https://www.targetedonc.com/view/perioperative-toripalimab-plus-chemotherapy-meets-final-phase-3-end-points2026-05-28T10:00:00Z2026-05-28T10:00:00Z https://www.targetedonc.com/view/fda-grants-priority-review-to-neladalkib-nda-for-alk-positive-nsclc2026-05-27T20:00:00Z2026-05-27T20:00:00Z https://www.targetedonc.com/view/study-reveals-patient-oncologist-gaps-in-post-cbtki-cll-treatment-preferences2026-05-27T19:00:00Z2026-05-27T19:00:00Z https://www.targetedonc.com/view/decisions-treat-progressive-desmoid-tumors2026-05-27T17:00:00Z2026-05-27T17:00:00Z https://www.targetedonc.com/view/allogeneic-car-t-may-expand-access-to-community-based-treatment2026-05-27T15:00:00Z2026-05-27T15:00:00Z https://www.targetedonc.com/view/daraxonrasib-demand-grows-amid-expanded-access-rollout-in-metastatic-pdac2026-05-27T14:00:00Z2026-05-27T14:00:00Z https://www.targetedonc.com/view/fda-extends-action-date-for-camizestrant-in-advanced-breast-cancer2026-05-27T12:30:00Z2026-05-27T12:30:00Z https://www.targetedonc.com/view/selecting-second-line-therapy-after-ici-progression-in-metastatic-ccrcc2026-05-26T21:00:00Z2026-05-26T21:00:00Z https://www.targetedonc.com/view/considerations-in-the-first-line-setting-in-polycythemia-vera2026-05-26T19:34:14.253Z2026-05-26T19:34:14.253Z https://www.targetedonc.com/view/insights-car-prism-car-t-eradicate-smoldering-myeloma2026-05-26T17:00:00Z2026-05-26T17:00:00Z https://www.targetedonc.com/view/analysis-highlights-rpfs-os-correlation-with-frontline-talazoparib-enzalutamide-in-mcrpc2026-05-26T13:24:47.086Z2026-05-26T13:24:47.086Z https://www.targetedonc.com/view/durvalumab-regimen-yields-manageable-safety-profile-in-bcg-naive-nmibc2026-05-25T20:33:00.705Z2026-05-25T20:33:00.705Z https://www.targetedonc.com/view/hafnium-oxide-nanoparticles-show-feasibility-in-stage-3-lung-cancer2026-05-25T10:00:00Z2026-05-25T10:00:00Z https://www.targetedonc.com/view/consolidation-cema-cel-shows-favorable-safety-mrd-positive-dlbcl2026-05-24T15:00:00Z2026-05-24T15:00:00Z https://www.targetedonc.com/view/nivolumab-plus-ipilimumab-emerges-as-a-go-to-regimen-for-frontline-hcc2026-05-24T10:00:00Z2026-05-24T10:00:00Z https://www.targetedonc.com/view/futility-analysis-supports-continued-evaluation-cema-cel-dlbcl2026-05-23T15:00:00Z2026-05-23T15:00:00Z https://www.targetedonc.com/view/fda-backs-protocol-changes-for-lp-300-trial-in-non-small-cell-lung-cancer2026-05-23T10:00:00Z2026-05-23T10:00:00Z https://www.targetedonc.com/view/phase-2-outcomes-show-potential-of-cilta-cel-in-smoldering-myeloma2026-05-22T21:00:00Z2026-05-22T21:00:00Z https://www.targetedonc.com/view/fda-grants-rpdd-and-odd-to-fl118-for-osteosarcoma2026-05-22T19:00:00Z2026-05-22T19:00:00Z https://www.targetedonc.com/view/assessing-genomic-assays-in-early-stage-invasive-breast-cancer2026-05-22T17:00:00Z2026-05-22T17:00:00Z https://www.targetedonc.com/view/fda-approves-datopotamab-deruxtecan-for-tnbc2026-05-22T14:37:33.504Z2026-05-22T14:37:33.504Z https://www.targetedonc.com/view/imetelstat-sustains-significant-survival-benefit-in-r-r-myelofibrosis2026-05-22T13:30:00Z2026-05-22T13:30:00Z https://www.targetedonc.com/view/novel-car-t-targeting-kappa-myeloma-antigen-enters-first-in-human-trial2026-05-22T13:00:00Z2026-05-22T13:00:00Z https://www.targetedonc.com/view/comparing-btki-monotherapies-in-frontline2026-05-22T12:56:25.490Z2026-05-22T12:56:25.490Z https://www.targetedonc.com/view/choosing-between-continuous-and-fixed-dosing-options-in-frontline2026-05-22T12:54:55.324Z2026-05-22T12:54:55.324Z https://www.targetedonc.com/view/zanubrutinib-safety-profile-in-cll-in-long-term-sequoia-follow-up2026-05-22T12:53:36.542Z2026-05-22T12:53:36.542Z